E-viri
Recenzirano
Odprti dostop
-
Naveja, Jose J.; Madariaga-Mazón, Abraham; Flores-Murrieta, Francisco; Granados-Montiel, Julio; Maradiaga-Ceceña, Marco; Alaniz, Víctor Duarte; Maldonado-Rodriguez, Maricruz; García-Morales, Jazmín; Senosiain-Peláez, Juan Pablo; Martinez-Mayorga, Karina
Drug discovery today, 01/2021, Letnik: 26, Številka: 1Journal Article
Display omitted •Treatment for moderately ill COVID-19 patients might arise from drug repurposing•RdRp, spike protein, and Mpro are relevant SARS-CoV-2 molecular targets.•Targeting human furin may contain viral infection and inflammation.•Molecular docking and clinical experience is useful for drug repurposing. Several clinical trials to treat Coronavirus 2019 (COVID-19) are in progress around the world. Some of them rely on clinical experience, whereas others include computational predictions. Here, we provide an overview of current efforts in the search for COVID-19 therapies, focusing on structural information of relevant targets. We elaborate on a robust pharmacological rationale for the repurposing of existing drugs, highlighting key advantages of dual therapies with antiviral and anti-inflammatory activity. Furthermore, we provide a consensus list of molecules that could undergo preliminary randomized clinical trials against COVID-19.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.